Drug Profile
Research programme: antibody therapies - Laboratorios Liomont
Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Laboratorios Liomont
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 28 Jul 2020 No recent reports of development identified for research development in Unspecified in Mexico (Parenteral)
- 02 Jun 2016 Laboratorios Liomont and Selexis enter into a commercial license agreement for the use of Selexis’ technology and proprietary CHO-K1 cell line for the development of antibody therapies